Recovery from ischemic acute kidney injury by spironolactone administration

Nephrology Dialysis Transplantation

Volumn 27, Issue 8, 2012, Pages 3160-3169

  Sánchez Pozos, Katy ^a,b   Barrera Chimal, Jonatan ^a,b   Garzón Muvdi, Juan ^a,b   Pérez Villalva, Rosalba ^a,b   Rodríguez Romo, Roxana ^a,b   Cruz, Cristino ^b   Gamba, Gerardo ^a,b   Bobadilla, Norma A ^a,b  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

AKI treatment; endothelin; renal dysfunction; Rho kinase

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ENDOTHELIN; HEAT SHOCK PROTEIN 72; KIDNEY INJURY MOLECULE 1; MESSENGER RNA; MINERALOCORTICOID RECEPTOR; PROTEIN; RHO KINASE; SPIRONOLACTONE;

ABDOMINAL SURGERY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; ISCHEMIC ACUTE KIDNEY INJURY; KIDNEY BLOOD FLOW; KIDNEY DYSFUNCTION; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY PERFUSION; KIDNEY TUBULE DAMAGE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RAT; RECEPTOR UPREGULATION; RENAL PROTECTION; REPERFUSION; SHAM PROCEDURE;

ACUTE KIDNEY INJURY; ALDOSTERONE; ANIMALS; DRUG ADMINISTRATION SCHEDULE; HSP72 HEAT-SHOCK PROTEINS; KIDNEY TUBULES; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; RATS; RATS, WISTAR; RECEPTOR, ANGIOTENSIN, TYPE 1; RENAL CIRCULATION; REPERFUSION INJURY; SPIRONOLACTONE; UP-REGULATION;

EID: 84864585183     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs014     Document Type: Article

References (61)

1. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66: 486-491.
2. Kelly KJ. Acute renal failure: much more than a kidney disease. Semin Nephrol 2006; 26: 105-113.
3. Liano F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. Kidney Int 1996; 50: 811-818.
4. Waikar SS, Curhan GC, Wald R et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006; 17: 1143-1150.
5. Cerda J, Lameire N, Eggers P et al. Epidemiology of acute kidney injury. Clin J Am Soc Nephrol 2008; 3: 881-886.
6. Mosier MJ, Pham TN, Klein MB et al. Early acute kidney injury predicts progressive renal dysfunction and higher mortality in severely burned adults. J Burn Care Res 2010; 31: 83-92.
7. Block CA, Schoolwerth AC. Acute renal failure: outcomes and risk of chronic kidney disease. Minerva Urol Nefrol 2007; 59: 327-335.
8. Hsu CY, Ordonez JD, Chertow GM et al. The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 2008; 74: 101-107.
9. Chertow GM, Burdick E, Honour M et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005; 16: 3365-3370.
10. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
11. Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
12. Rocha R, Chander PN, Khanna K et al. Mineralocorticoid blockade reduces vascular injury in stroke-prone hypertensive rats. Hypertension 1998; 31: 451-458.
13. Rocha R, Chander PN, Zuckerman A et al. Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats. Hypertension 1999; 33: 232-237.
14. Rocha R, Stier CT, Jr, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878.
15. Hollenberg NK. Aldosterone in the development and progression of renal injury. Kidney Int 2004; 66: 1-9.
16. Aldigier JC, Kanjanbuch T, Ma LJ et al. Regression of existing glomerulosclerosis by inhibition of aldosterone. J Am Soc Nephrol 2005; 16: 3306-3314.
17. Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis 2005; 46: 45-51.
18. Sato A, Hayashi K, Naruse M et al. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003; 41: 64-68.
19. Boldyreff B, Wehling M. Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells. Nephrol Dial Transplant 2003; 18: 1693-1695.
20. Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in the glomerular microcirculation. J Am Soc Nephrol 2003; 14: 2255-2263.
21. Gros R, Ding Q, Armstrong S et al. Rapid effects of aldosterone on clonal human vascular smooth muscle cells. Am J Physiol Cell Physiol 2007; 292: C788-C794.
22. Leopold JA, Dam A, Maron BA et al. Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 2007; 13: 189-197.
23. Feria I, Pichardo I, Juarez P et al. Therapeutic benefit of spironolactone in experimental chronic cyclosporine A nephrotoxicity. Kidney Int 2003; 63: 43-52.
24. Perez-Rojas JM, Derive S, Blanco JA et al. Renocortical mRNA expression of vasoactive factors during spironolactone protective effect in chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2005; 289: F1020-F1030.
25. Perez-Rojas J, Blanco JA, Cruz C et al. Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol 2007; 292: F131-F139.
26. Mejia-Vilet JM, Ramirez V, Cruz C et al. Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 2007; 293: F78-F86.
27. Ramirez V, Trujillo J, Valdes R et al. Adrenalectomy prevents renal ischemia-reperfusion injury. Am J Physiol Renal Physiol 2009; 297: F932-F942.
28. Matsumoto M, Makino Y, Tanaka T et al. Induction of renoprotective gene expression by cobalt ameliorates ischemic injury of the kidney in rats. J Am Soc Nephrol 2003; 14: 1825-1832.
29. Pedraza-Chaverri J, Tapia E, Bobadilla N. Ischemia-reperfusion induced acute renal failure in the rat is ameliorated by the spin-trapping agent alpha-phenyl-N-tert-butyl nitrone (PBN). Ren Fail 1992; 14: 467-471.
30. Fujii T, Sugiura T, Ohkita M et al. Selective antagonism of the postsynaptic alpha(1)-adrenoceptor is protective against ischemic acute renal failure in rats. Eur J Pharmacol 2007; 574: 185-191.
31. Sadis C, Teske G, Stokman G et al. Nicotine protects kidney from renal ischemia/reperfusion injury through the cholinergic antiinflammatory pathway. PLoS ONE 2007; 2: e469..
32. Chatterjee PK, Patel NS, Sivarajah A et al. GW274150, a potent and highly selective inhibitor of iNOS, reduces experimental renal ischemia/reperfusion injury. Kidney Int 2003; 63: 853-865.
33. Suzuki S, Maruyama S, Sato W et al. Geranylgeranylacetone ameliorates ischemic acute renal failure via induction of Hsp70. Kidney Int 2005; 67: 2210-2220.
34. Perez-Rojas JM, Blanco JA, Gamba G et al. Low calorie commercial sugar is a sensitive marker of glomerular filtration rate. Kidney Int 2005; 68: 1888-1893.
35. Davidson DW, Sackner MA. Simplification of the anthrone method for the determination of inulin in clearance studies. J Lab Clin Med 1963; 62: 351-356.
36. Henry RJ, Sobel C, Segalove M. Turbidimetric determination of proteins with sulfosalicylic and tricholoroacetic acids. Proc Soc Exp Biol Med 1956; 92: 748-751.
37. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
38. Barrera-Chimal J, Perez-Villalva R, Cortes-Gonzalez C et al. Hsp72 is an early and sensitive biomarker to detect acute kidney injury. EMBO Mol Med 2011; 3: 5-20.
39. Shimokawa H, Takeshita A. Rho-kinase is an important therapeutic target in cardiovascular medicine. Arterioscler Thromb Vasc Biol 2005; 25: 1767-1775.
40. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006; 17: 1503-1520.
41. Ramirez V, Mejia-Vilet JM, Hernandez D et al. Radicicol, a heat shock protein 90 inhibitor, reduces glomerular filtration rate. Am J Physiol Renal Physiol 2008; 295: F1044-F1051.
42. Vaidya VS, Ozer JS, Dieterle F et al. Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol 2010; 28: 478-485.
43. Vaidya VS, Ford GM, Waikar SS et al. A rapid urine test for early detection of kidney injury. Kidney Int 2009; 76: 108-114.
44. Vaidya VS, Ramirez V, Ichimura T et al. Urinary kidney injury molecule- 1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol 2006; 290: F517-F529.
45. Han WK, Wagener G, Zhu Y et al. Urinary biomarkers in the early detection of acute kidney injury after cardiac surgery. Clin J Am Soc Nephrol 2009; 4: 873-882.
46. Jassem W, Heaton ND. The role of mitochondria in ischemia/reperfusion injury in organ transplantation. Kidney Int 2004; 66: 514-517.
47. Fiebeler A, Luft FC. The mineralocorticoid receptor and oxidative stress. Heart Fail Rev 2005; 10: 47-52.
48. Miyata K, Rahman M, Shokoji T et al. Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 2005; 16: 2906-2912.
49. Caron A, Desrosiers RR, Beliveau R. Kidney ischemia-reperfusion regulates expression and distribution of tubulin subunits, beta-actin and rho GTPases in proximal tubules. Arch Biochem Biophys 2004; 431: 31-46.
50. Sun GP, Kohno M, Guo P et al. Involvements of rho-kinase and tgf- Beta pathways in aldosterone-induced renal injury. J Am Soc Nephrol 2006; 17: 2193-2201.
51. Yao L, Romero MJ, Toque HA et al. The role of RhoA/Rho kinase pathway in endothelial dysfunction. J Cardiovasc Dis Res 2010; 1: 165-170.
52. Zhu L, Jiang R, Aoudjit L et al. Activation of RhoA in podocytes induces focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22: 1621-1630.
53. Kobayashi N, Hara K, Tojo A et al. Eplerenone shows renoprotective effect by reducing LOX-1-mediated adhesion molecule, PKCepsilon- MAPK-p90RSK, and Rho-kinase pathway. Hypertension 2005; 45: 538-544.
54. Prakash J, de Borst MH, Lacombe M et al. Inhibition of renal rho kinase attenuates ischemia/reperfusion-induced injury. J Am Soc Nephrol 2008; 19: 2086-2097.
55. Barton M, Yanagisawa M. Endothelin: 20 years from discovery to therapy. Can J Physiol Pharmacol 2008; 86: 485-498.
56. Wong S, Brennan FE, Young MJ et al. A direct effect of aldosterone on endothelin-1 gene expression in vivo. Endocrinology 2007; 148: 1511-1517.
57. Wolf SC, Schultze M, Risler T et al. Stimulation of serum- and glucocorticoid- regulated kinase-1 gene expression by endothelin-1. Biochem Pharmacol 2006; 71: 1175-1183.
58. Doi T, Sakoda T, Akagami T et al. Aldosterone induces interleukin- 18 through endothelin-1, angiotensin II, Rho/Rho-kinase, and PPARs in cardiomyocytes. Am J Physiol Heart Circ Physiol 2008; 295: H1279-H1287.
59. Gumz ML, Popp MP, Wingo CS et al. Early transcriptional effects of aldosterone in a mouse inner medullary collecting duct cell line. Am J Physiol Renal Physiol 2003; 285: F664-F673.
60. Stow LR, Gumz ML, Lynch IJ et al. Aldosterone modulates steroid receptor binding to the endothelin-1 gene (edn1). J Biol Chem 2009; 284: 30087-30096.
61. Molinas SM, Cortes-Gonzalez C, Gonzalez-Bobadilla Y et al. Effects of losartan pretreatment in an experimental model of ischemic acute kidneyinjury. Nephron Exp Nephrol 2009; 112: e10-e19